IGFBP2 and metabolic dysfunction-associated steatotic liver disease: In addition, Fahlbusch et al. [82] and Yang et al. [83] reported that circulating IGFBP2 levels were lower among obese NAFLD patients compared with that of healthy controls whereas weight loss restored the plasma IGFBP2 level accompanied by a downregulation of fatty liver contents [82].